The Lynx Group
Cholangiocarcinoma News

Molecular Profiling Should Now Be Routine Practice in Patients with CCA

September/October 2021, Vol 2, No 3
Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers

Dear Colleagues,

This issue of CCA News features yet another exciting FDA approval for cholangiocarcinoma (CCA), ivosidenib, which was recently approved for CCA with IDH1 mutation. This is the third drug approved for CCA in the past 2 years, highlighting the critical role of molecular profiling in this cancer. Up to 20% of patients with intrahepatic CCA have IDH1 mutation, and the ClarIDHy phase 3 study demonstrated improvement in progression-free survival with ivosidenib versus placebo for chemorefractory disease. The FDA also approved the Oncomine Dx Target Test for IDH1 mutations.

At the CCA Summit during the 2021 American Society of Clinical Oncology meeting, Mitesh J. Borad, MD, from the Mayo Clinic in Phoenix reviewed some of the key topics presented. The FIGHT-202 updated results showed an overall response rate (ORR) of 37%, with an 8.1-month duration of response—remarkable figures for chemorefractory CCA with FGFR2 fusions. The FOENIX-CCA2 study revealed that the ORR with futibatinib was 41.7%, and the median duration of response was 9.7 months, along with a favorable impact on quality of life.

FGFR2 fusions occur in 10% to 16% of patients with intrahepatic CCA, according to a real-life study by Rachna T. Shroff, MD, from the University of Arizona Cancer Center, and colleagues, who reviewed 500 patients with CCA. These patients may have a favorable prognosis. Shalini Makawita, MD, from M.D. Anderson Cancer Center, explored the mutational profiles of patients with IDH1/IDH2-altered CCA. These subtypes have a unique genetic profile compared with wild-type IDH, and these tumors have a low prevalence of genomic biomarkers. These data are important when studying primary resistance, and for future approaches to combination therapies.

In a recent review article, Tanios S. Bekaii-Saab, MD, of the Mayo Clinic in Phoenix, and colleagues emphasized the importance of next-generation sequencing for improving personalized treatment for CCA; it is critical that an FDA-approved test be used. Molecular profiling is, however, not routinely performed in patients with CCA, according to this article.

Megan C. Roberts, PhD, from the University of North Carolina at Chapel Hill, reported that the 2 main reasons for lack of genomic testing are clinical utility and relevance. Clearly, there is a role for education of oncologists, with programs such as Mutations Matter from the Cholangiocarcinoma Foundation. Access to the novel therapies for CCA remains challenging, and, therefore, expanded access programs, as highlighted by Melinda Bachini of the Cholangiocarcinoma Foundation, are of significant value for patients with this disease.

Bruno C. Odisio, MD, FSIR, Interventional Radiologist at M.D. Anderson Cancer Center, reviews several interesting articles in this issue from 2 interventional oncology meetings, including a study from Matthew T. Quirk, MD, of the University of California at Los Angeles, that disputes the dogma regarding metastatic spread from transperitoneal biopsies for CCA, and another study from Germany, on the role of intra-arterial SIR-spheres therapy (or radioembolization) for CCA. Liver-directed therapies are underutilized, and further investigation is needed.

Flavio G. Rocha, MD, Director of Research, Digestive Disease Institute at the University of Washington in Seattle, has provided a succinct review of abstracts from the 2021 Americas Hepato-Pancreato-Biliary Association meeting. Natalia Paez-Arango, MD, and Hop S. Tran Cao, MD, of M.D. Anderson Cancer Center, reported their experience with neoadjuvant chemotherapy for intrahepatic CCA; this approach appears feasible and may prolong survival, although tissue assessment for pathologic response remains challenging.

Guergana Panayotova, MD, and Keri E. Lunsford, MD, PhD, from Rutgers, New Jersey Medical School, analyzed SEER data showing that liver transplantation, along with surgery, offered the best survival for intrahepatic CCA. These and other important developments are featured in this issue.

We look forward to your participation in the upcoming 3rd Annual CCA Summit, October 21-22, 2021, in New Orleans!

Sincerely,

Milind Javle, MD

Milind M. Javle, MD
Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers

Related Items

New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Rapid Trajectory of Clinical Research in Biliary Tract Cancers
By Milind M. Javle, MD
March 2022, Vol 3, No 1
The 2022 ASCO GI Cancers Symposium clearly highlighted the rapid trajectory of clinical research in biliary tract cancers. One of the most eagerly anticipated studies, TOPAZ-1, was presented by Do-Youn Oh, MD, PhD, from Seoul National University Hospital in South Korea. This phase 3 clinical trial enrolled 685 patients and investigated the addition of the PD-L1–directed agent durvalu­mab to gemcitabine and cisplatin chemotherapy backbone versus these chemotherapies alone. The results demonstrated a statistically significant improvement in overall survival (OS), overall response rate (ORR), and progression-free survival (PFS), without dose-limiting toxicities.
Hot Topics at ASCO-GI 2022
By Milind M. Javle, MD
Videos
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.
Cholangiocarcinoma Research Continues to Thrive
By Milind M. Javle, MD
December 2021, Vol 2, No 4
The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic.
Mechanisms of Resistance to FGFR Inhibitors
By Jesús Bañales, PhD; Antoine Hollebecque, MD; Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc
Videos
Drs Javle, Bañales, and Hollebecque discuss the innate and acquired resistance pathways to FGFR inhibitors in cholangiocarcinoma and how these pathways can have important effects on clinical outcomes. They also look ahead to ongoing clinical trials evaluating next-generation FGFR inhibitors that may be able to overcome resistance mechanisms and improve progression-free and overall survival in cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: